The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. [electronic resource]
Producer: 20000601Description: 838-46 p. digitalISSN:- 1078-0432
- Aged
- Antigens, Surface
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biopsy
- Bone Neoplasms -- drug therapy
- Carboxypeptidases -- analysis
- Cheilitis -- chemically induced
- Dyspnea -- chemically induced
- Exanthema -- chemically induced
- Fatigue -- chemically induced
- Glutamate Carboxypeptidase II
- Hematologic Diseases -- chemically induced
- Humans
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Ki-67 Antigen -- analysis
- Liver -- enzymology
- Male
- Middle Aged
- Prostate -- chemistry
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- drug therapy
- Recombinant Proteins
- Transaminases -- drug effects
- Treatment Outcome
- Tretinoin -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.